Exclusion of patients with renal impairment from phase 3 randomized controlled trials in hematologic malignancies.

Phase 3 randomized controlled trials (RCTs) are key for assessing the efficacy and safety of new drugs used in hematologic malignancies. Up to 50% of patients with hematologic malignancies have renal impairment. The objective of this study was to per…

Preview only. Read the full abstract at the source